GLPG (Galapagos NV) Inventories, Other : $41.6 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Galapagos NV's other inventories for the quarter that ended in Mar. 2025 was $41.6 Mil.

Galapagos NV's quarterly other inventories declined from Sep. 2024 ($72.8 Mil) to Dec. 2024 ($0.0 Mil) but then increased from Dec. 2024 ($0.0 Mil) to Mar. 2025 ($41.6 Mil).

Galapagos NV Inventories, Other Historical Data

The historical data trend for Galapagos NV's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Inventories, Other Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Other

Get a 7-Day Free Trial

0.39

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Inventories, Other	Get a 7-Day Free Trial															87.56	68.21	72.77	-	41.64

Galapagos NV Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.